The Manufacturers Life Insurance Company Has $272,000 Stock Position in Liquidia Co. (NASDAQ:LQDA)

The Manufacturers Life Insurance Company lifted its stake in shares of Liquidia Co. (NASDAQ:LQDA) by 25.2% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 22,706 shares of the company’s stock after purchasing an additional 4,572 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Liquidia were worth $272,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Squarepoint Ops LLC boosted its stake in Liquidia by 53.4% in the second quarter. Squarepoint Ops LLC now owns 82,272 shares of the company’s stock valued at $987,000 after buying an additional 28,638 shares in the last quarter. Marshall Wace LLP acquired a new stake in Liquidia in the second quarter valued at about $545,000. HighVista Strategies LLC acquired a new stake in Liquidia in the second quarter valued at about $1,461,000. Profund Advisors LLC boosted its stake in Liquidia by 31.6% in the second quarter. Profund Advisors LLC now owns 14,434 shares of the company’s stock valued at $173,000 after buying an additional 3,466 shares in the last quarter. Finally, Quest Partners LLC acquired a new stake in Liquidia in the second quarter valued at about $27,000. 64.54% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Caligan Partners Lp acquired 150,000 shares of the firm’s stock in a transaction dated Friday, August 30th. The stock was purchased at an average price of $9.51 per share, for a total transaction of $1,426,500.00. Following the completion of the acquisition, the director now directly owns 6,994,997 shares in the company, valued at $66,522,421.47. The trade was a 0.00 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, insider Rajeev Saggar sold 2,260 shares of the company’s stock in a transaction on Monday, October 14th. The stock was sold at an average price of $11.11, for a total transaction of $25,108.60. Following the completion of the sale, the insider now owns 207,383 shares in the company, valued at approximately $2,304,025.13. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Caligan Partners Lp purchased 150,000 shares of the firm’s stock in a transaction that occurred on Friday, August 30th. The shares were bought at an average price of $9.51 per share, with a total value of $1,426,500.00. Following the acquisition, the director now directly owns 6,994,997 shares of the company’s stock, valued at $66,522,421.47. This represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. Insiders sold a total of 20,858 shares of company stock worth $228,724 over the last quarter. 31.60% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the company. BTIG Research reduced their price objective on Liquidia from $29.00 to $25.00 and set a “buy” rating on the stock in a research note on Monday, August 19th. HC Wainwright dropped their target price on Liquidia from $32.00 to $29.00 and set a “buy” rating for the company in a research report on Tuesday, August 20th. Scotiabank assumed coverage on Liquidia in a research report on Wednesday. They issued a “sector outperform” rating and a $30.00 target price for the company. Raymond James upgraded Liquidia from an “outperform” rating to a “strong-buy” rating in a research report on Monday, August 19th. Finally, Lifesci Capital started coverage on Liquidia in a research report on Thursday, October 3rd. They issued an “outperform” rating and a $30.00 target price for the company. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, Liquidia presently has an average rating of “Moderate Buy” and a consensus target price of $24.67.

Liquidia Stock Performance

Shares of LQDA opened at $11.14 on Friday. Liquidia Co. has a 52-week low of $5.71 and a 52-week high of $16.99. The business’s 50 day moving average price is $10.41 and its two-hundred day moving average price is $11.94. The firm has a market cap of $851.25 million, a PE ratio of -7.14 and a beta of 0.22.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.02). Liquidia had a negative net margin of 755.46% and a negative return on equity of 183.57%. The business had revenue of $3.66 million during the quarter, compared to analyst estimates of $7.92 million. Research analysts predict that Liquidia Co. will post -1.69 EPS for the current fiscal year.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).